Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells $375,200.00 in Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of Aduro BioTech stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $9.38, for a total value of $375,200.00. Following the completion of the transaction, the insider now owns 213,921 shares in the company, valued at $2,006,578.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Aduro BioTech Inc (ADRO) opened at $8.20 on Thursday. Aduro BioTech Inc has a 1-year low of $6.01 and a 1-year high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The business had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share. equities research analysts forecast that Aduro BioTech Inc will post -1.28 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc boosted its holdings in shares of Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 1,043 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Aduro BioTech in the 3rd quarter worth approximately $127,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Aduro BioTech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares in the last quarter. SG Americas Securities LLC bought a new position in Aduro BioTech in the 3rd quarter worth approximately $167,000. Finally, Trexquant Investment LP bought a new position in Aduro BioTech in the 3rd quarter worth approximately $175,000. 45.19% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently weighed in on the company. Oppenheimer assumed coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 target price on the stock. HC Wainwright set a $18.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Finally, William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Aduro BioTech has an average rating of “Buy” and an average target price of $19.14.

WARNING: “Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells $375,200.00 in Stock” was first published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/07/insider-selling-aduro-biotech-inc-adro-insider-sells-375200-00-in-stock.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

What are top analysts saying about Aduro BioTech Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro BioTech Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit